同一突变,不同病程:扩展儿童纯合SAMHD1缺陷的临床谱
该研究回顾性分析3例携带相同纯合SAMHD1错义突变(c.625G>A; p.Gly209Ser)的儿科患者,发现其表型显著不同:慢性肌病为主型、经典干扰素病伴脂膜炎及颅内钙化、狼疮样结缔组织病伴钙质沉着和血管病变。所有患者接受JAK抑制剂(主要为托法替尼)治疗获部分至持续改善,中断治疗即复发。
要点
- 纯合SAMHD1缺陷在儿童中表型高度异质,可超越经典AGS5。
- 不明原因系统性炎症患儿应考虑SAMHD1突变,即使神经影像正常。
- JAK抑制剂对多样表型有效,支持干扰素驱动发病,中断治疗易复发。
核心结论
- 纯合SAMHD1缺陷在儿童中呈现显著表型异质性,延伸至经典AGS5之外。
- 不同表型对JAK抑制的临床反应支持共享的干扰素驱动发病机制。
- 早期基因诊断有助于指导靶向治疗。
研究设计与样本
- 回顾性分析3例在三级中心评估的儿科患者,均携带相同纯合SAMHD1错义突变(c.625G>A; p.Gly209Ser)。
- 全外显子测序确认所有患者携带该致病性变异。
主要发现
- 3例患者表型显著不同:慢性肌病为主型无中枢神经系统受累、经典干扰素病伴脂膜炎及颅内钙化、狼疮样结缔组织病伴钙质沉着和血管病变。
- 神经影像学表现从正常到经典AGS特征不等。
- 所有患者接受JAK抑制剂(主要为托法替尼)治疗,获部分至持续临床改善。
- 治疗中断期间均出现疾病复发。
临床怎么用
- 对不明原因系统性炎症的儿童应考虑SAMHD1突变,即使缺乏典型神经影像学发现。
- JAK抑制剂(如托法替尼)可用于纯合SAMHD1缺陷相关表型,治疗中断易复发,需持续用药。
- 早期基因诊断有助于指导靶向治疗。
局限性
- 回顾性研究,样本量仅3例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Homozygous loss-of-function mutations in SAMHD1 classically cause Aicardi-Goutières syndrome type 5 (AGS5), characterized by neuroinflammation and intracranial calcifications. Increasing evidence suggests a broader clinical spectrum. We aimed to describe the phenotypic heterogeneity associated with a single homozygous SAMHD1 variant in paediatric patients and to highlight diagnostic and therapeutic implications. METHODS: We retrospectively reviewed three paediatric patients evaluated at a tertiary centre who carried the same homozygous SAMHD1 missense variant (c.625G>A; p. Gly209Ser). Clinical features, laboratory findings, imaging results, genetic analyses, treatments and longitudinal responses were extracted from medical records. Whole-exome sequencing confirmed the pathogenic variant in all patients. RESULTS: Despite sharing an identical homozygous SAMHD1 mutation, the patients exhibited markedly divergent phenotypes: a chronic myopathy-dominant presentation without central nervous system involvement, a classical interferonopathy with panniculitis and intracranial calcifications and a lupus-like connective tissue disease phenotype with calcinosis and vasculopathy. Neuroimaging findings ranged from normal to classical AGS features. All patients received Janus kinase (JAK) inhibitors, predominantly tofacitinib, resulting in partial to sustained clinical improvement. Disease flares consistently occurred during treatment interruptions, emphasizing the importance of continuous therapy. CONCLUSIONS: Homozygous SAMHD1 deficiency demonstrates striking phenotypic heterogeneity in childhood, extending beyond classical AGS. SAMHD1 mutations should be considered in children with unexplained systemic inflammation, even in the absence of typical neuroimaging findings. Clinical responses to JAK inhibition across diverse phenotypes support a shared interferon-driven pathogenesis and highlight the value of early genetic diagnosis to guide targeted therapy.
引用
- Emreol HE, Ünal D, Ayvaz DNC, et al. One mutation, divergent journeys: expanding the clinical spectrum of homozygous SAMHD1 deficiency in childhood. Rheumatology (Oxford). 2026. PMID: 41496005. doi:10.1093/rheumatology/keaf695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。